

dr. **Mihály Krámer** was born in 1951. He obtained the chemistry masters degree in 1974 at Eötvös Loránd University. He had worked as a post-graduate student, as assistant, then assistant professor at the Biochemistry Institute of Semmelweis University under the supervision of late professor István Horváth. He defended his university doctors degree in 1983 in the topic of the growth regulation of *E. coli*. During 1989 and 1991 he had worked in the United States at the Washington University in St. Louis as guest researcher. Turning back he became the head of the diagnostics branch of Sanofi Diagnostics Pasteur (latter called BioRad) for a year as a coworker of Chinoin Pharmaceuticals Co. Here he was primarily responsible for the Hungarian introduction of the viral- and other microbiological diagnostics (first of all ELISA technology based products). From September 1995 on he has been the managing director of Izinta Trading Ltd. Under his management the microbiology and virus diagnostics branch became one of the keystones of of Izinta Ltd., and the company became market leader in case of an array of tests. As a manager he is responsible for special projects in the diagnostics of *Helicobacter pylori* infections. Under his supervision in 1998 Izinta Ltd introduced the urea breath test in Hungary. UBT became the gold standard of the *Helicobacter* infection diagnosis in gastroenterology. They developed the ¹³C-urea heavy isotope pill, as the breath test substrate which development is under European registration. In 2006 the company procured the patent rights of the BactFISH molecular biological technique to determine the antibiotic resistance of *H. pylori* in on step to the most important therapeutical antibiotic clarythromycin. This widely accepted technique makes possible the simultaneous detection of clarythromycin resistant and sensitive cells from stomach biopsy using the FISH technique obviateing culture. Based on the results of more then ten thousand tests performed till now this rapid diagnostic technique seems to be therapeutically extremely important in the clinical phase of gastric ulcer treatment.

Dr Krámer and the Izinta Ltd. is always present at congresses and participates in the work of the Hungarian Society for Microbiology.